Celgene Share Price

CELG

Delayed Nasdaq Other stock markets 02:30:00 21/11/2019 am IST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

15/23/15	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/21/08	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

07/21/07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
25/21/25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
02/21/02	BX Swiss AG startet Handel in neuem Bondsegment
07/20/07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
03/20/03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	7.7TCr 6.75TCr 6.21TCr 5.77TCr 11TCr 7,34800Cr 11TCr 74TCr 29TCr 3,60700Cr 29TCr 28TCr 12,50600Cr	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	9.13TCr 7.99TCr 7.36TCr 6.83TCr 13TCr 8,70500Cr 13TCr 88TCr 34TCr 4,27300Cr 34TCr 34TCr 14,81500Cr	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

15/23/15	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
08/21/08	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
22/21/22	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
23/21/23	Celgene Corporation Issues Notice of Redemption of Notes	CI
04/21/04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
05/21/05	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
23/20/23	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
05/20/05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
23/20/23	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
22/20/22	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
26/20/26	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
11/20/11	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
04/20/04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

28/23/28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
25/22/25	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
29/22/29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
25/22/25	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
04/21/04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	1.3TCr 1.14TCr 1.05TCr 973.61Cr 1.85TCr 1,24000Cr 1.87TCr 13TCr 4.89TCr 61TCr 4.88TCr 4.78TCr 2,11100Cr	1.53TCr 1.34TCr 1.23TCr 1.14TCr 2.17TCr 1,45800Cr 2.2TCr 15TCr 5.74TCr 72TCr 5.74TCr 5.61TCr 2,48100Cr
Net income	294Cr 257.49Cr 237.16Cr 220.14Cr 418.03Cr 28TCr 423.68Cr 2.84TCr 1.1TCr 14TCr 1.1TCr 1.08TCr 48TCr	404.6Cr 354.35Cr 326.37Cr 302.95Cr 575.29Cr 39TCr 583.07Cr 3.91TCr 1.52TCr 19TCr 1.52TCr 1.49TCr 66TCr
Net Debt	379.3Cr 332.19Cr 305.97Cr 284Cr 539.32Cr 36TCr 546.61Cr 3.66TCr 1.43TCr 18TCr 1.42TCr 1.39TCr 62TCr	1.42TCr 1.25TCr 1.15TCr 1.06TCr 2.02TCr 1,35700Cr 2.05TCr 14TCr 5.34TCr 67TCr 5.34TCr 5.22TCr 2,30900Cr

Celgene Share Price

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile